TRPC6 and cardiac hypertrophy: Notably, upregulation of TRPC6 in myocytes plays a role in cardiac hypertrophy (Kuwahara et al., 2006; Onohara et al., 2006; Xie et al., 2012; Wu et al., 2010), and gain-of-function mutations of TRPC6 contribute to hereditary focal segmental glomerulosclerosis (FSGS), a renal disorder characterized by podocyte injury and a potential cause of end stage renal disease (Reiser et al., 2005; Heeringa et al., 2009; Ilatovskaya and Staruschenko, 2015; Mottl et al., 2013; Winn et al., 2005).